Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients - Trial NCT06383559
Access comprehensive clinical trial information for NCT06383559 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and is currently Recruiting. The study focuses on Gastric Cancer. Target enrollment is 39 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tianjin Medical University Cancer Institute and Hospital
Timeline & Enrollment
Phase 2
Dec 01, 2023
Sep 01, 2026
Primary Outcome
ORR
Summary
This is a multi-center, prospective, open label phase 2 study evaluating the safety and
 efficacy of standard first-line chemotherapy XELOX regimen combined with Sintilimab
 (anti-PD-1 antibody) and Lenvatinib in the treatment of advanced AFP-positive gastric cancer.
 This study was conducted in the Department of Gastrointestinal Medical Oncology, Tianjin
 Medical University Cancer Institute and Hospital. Previous phase 1 dose escalation study
 (TJMUCH-GI-GC002) has demonstrated that such combinational pattern was well tolerated with
 promising efficacy. In this study, patients with AFP-positive and HER-2-negative advanced
 gastric cancer who had not received palliative systematic treatment in the past will be
 enrolled. Patients who met the inclusion criteria were treated with XELOX regimen combined
 with Sintilimab plus Lenvatinib every 3 weeks until disease progression or intolerable
 adverse reactions or death. The treatment regimen is XELOX chemotherapy (oxaliplatin 130mg/
 m2, d1, capecitabine 850-1250 mg/m2, bid, d1-14, every 3 weeks) in combination with
 Sintilimab (=60kg, 200 mg; 60kg, 3mg/kg; intravenous infusion, every 3 weeks) plus
 Lenvatinib (determined from previous phase 1 study, 16mg, orally once a day). Patients
 received regular and periodic reviews, with imaging evaluations every 6 weeks. Safety will be
 evaluated by AE and laboratory tests.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06383559
Non-Device Trial